2024 Q3 Form 10-Q Financial Statement

#000168316824006420 Filed on September 16, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2023 Q4 2023 Q3
Revenue $12.00K $32.50K
YoY Change -63.08%
Cost Of Revenue $0.00 $0.00
YoY Change
Gross Profit $12.00K $32.50K
YoY Change -63.08%
Gross Profit Margin 100.0% 100.0%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $18.05K $10.00K
YoY Change 80.41%
Operating Profit -$6.048K $22.50K
YoY Change -126.88%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.048K $22.50K
YoY Change -126.88%
Income Tax
% Of Pretax Income
Net Earnings -$6.048K $22.50K
YoY Change -126.88%
Net Earnings / Revenue -50.4% 69.22%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 12.00M shares 5.000M shares
Diluted Shares Outstanding 12.00M shares 5.000M shares

Balance Sheet

Concept 2024 Q3 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $109.3K $22.10K $20.99K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $2.500K $0.00
Total Short-Term Assets $114.0K $24.27K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $114.0K $24.27K
Total Long-Term Assets $0.00 $0.00
Total Assets $114.0K $24.27K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $301.00 $4.594K
YoY Change
Accrued Expenses $0.00 $3.000K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $301.00 $22.39K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $301.00 $22.39K
Total Long-Term Liabilities
Total Liabilities $301.00 $22.39K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$26.80K $1.373K
YoY Change
Common Stock $1.200K $500.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $113.7K $1.873K $19.99K
YoY Change
Total Liabilities & Shareholders Equity $114.0K $24.27K
YoY Change

Cashflow Statement

Concept 2024 Q3 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$6.048K $22.50K
YoY Change -126.88%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--10-31
us-gaap Revenues
Revenues
82500 usd
us-gaap Net Income Loss
NetIncomeLoss
20994 usd
dei Entity Central Index Key
EntityCentralIndexKey
0002000762
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2024Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
0 usd
CY2023Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
0 usd
CY2024Q3 GMTH Due To Related Parties
DueToRelatedParties
0 usd
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-07-31
dei Entity File Number
EntityFileNumber
333-275887
dei Entity Registrant Name
EntityRegistrantName
GMTECH INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WY
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
93-3955846
dei Entity Address Address Line1
EntityAddressAddressLine1
45 Rockefeller Plaza
dei Entity Address Address Line2
EntityAddressAddressLine2
21F
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10111
dei City Area Code
CityAreaCode
(646) 508-0022
dei Local Phone Number
LocalPhoneNumber
508-0022
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12000000 shares
CY2024Q3 us-gaap Cash
Cash
109329 usd
CY2023Q4 us-gaap Cash
Cash
22099 usd
CY2024Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2500 usd
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
0 usd
CY2024Q3 us-gaap Deposits Assets Current
DepositsAssetsCurrent
2168 usd
CY2023Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
2168 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
113997 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
24267 usd
CY2024Q3 us-gaap Assets
Assets
113997 usd
CY2023Q4 us-gaap Assets
Assets
24267 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
301 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4594 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
0 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3000 usd
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14800 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
301 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22394 usd
CY2024Q3 us-gaap Liabilities
Liabilities
301 usd
CY2023Q4 us-gaap Liabilities
Liabilities
22394 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12000000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5000000 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1200 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
500 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
139300 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-26804 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1373 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
113696 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1873 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
113997 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24267 usd
CY2024Q3 us-gaap Revenues
Revenues
12000 usd
CY2023Q3 us-gaap Revenues
Revenues
32500 usd
us-gaap Revenues
Revenues
46800 usd
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
9500 usd
us-gaap Cost Of Revenue
CostOfRevenue
20000 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
12000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
32500 usd
us-gaap Gross Profit
GrossProfit
37300 usd
us-gaap Gross Profit
GrossProfit
62500 usd
CY2024Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
0 usd
CY2023Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
0 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
0 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
18000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18048 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10004 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
65477 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23506 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
18048 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
10004 usd
us-gaap Operating Expenses
OperatingExpenses
65477 usd
us-gaap Operating Expenses
OperatingExpenses
41506 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6048 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
22496 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28177 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
20994 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-6048 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
22496 usd
us-gaap Net Income Loss
NetIncomeLoss
-28177 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12000000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12000000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5000000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8111111 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8111111 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5000000 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1873 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
983 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2856 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
140000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-23112 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
119744 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-6048 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
113696 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1502 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2502 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
22496 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
19994 usd
us-gaap Net Income Loss
NetIncomeLoss
-28177 usd
us-gaap Net Income Loss
NetIncomeLoss
20994 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
2500 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-0 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4293 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
0 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
0 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-14800 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52770 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
20994 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
140000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
140000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
87230 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
20994 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22099 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
109329 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20994 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_840_eus-gaap--UseOfEstimates_z50aEvd96pV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Use of Estimates</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management uses estimates and assumptions in preparing these financial statements in accordance with US GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities in the balance sheets, and the reported revenue and expenses during the periods reported. Actual results may differ from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
14800 usd
us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<p id="xdx_84D_eus-gaap--RevenueRecognitionDeferredRevenue_zJIX7ApsrII3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Deferred Revenue</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred revenue consists of payments made in advance of services provided to customers. The deferred revenue balances as of July 31, 2024 and October 31, 2023 are $<span id="xdx_90A_eus-gaap--DeferredRevenueCurrent_iI_c20240731_zEMIECnlu39k">0</span> and $<span id="xdx_90E_eus-gaap--DeferredRevenueCurrent_iI_c20231031_zbIDKmH8H7a7">14,800</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14800 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Operating Lease Expense
OperatingLeaseExpense
13077 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
12051 usd
us-gaap Net Income Loss
NetIncomeLoss
-28177 usd
us-gaap Net Income Loss
NetIncomeLoss
20994 usd
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5917 usd
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
4409 usd
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
5917 usd
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
0 usd
us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
0 usd
us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4409 usd
CY2024Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
26804 usd
CY2024Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
5629 usd
CY2024Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
26804 usd
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0 usd
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2024Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
5629 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
0 usd
CY2024Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5629 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
-0 usd
CY2024Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-006420-index-headers.html Edgar Link pending
0001683168-24-006420-index.html Edgar Link pending
0001683168-24-006420.txt Edgar Link pending
0001683168-24-006420-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gmtech_ex3101.htm Edgar Link pending
gmtech_ex3102.htm Edgar Link pending
gmtech_ex32.htm Edgar Link pending
gmtech_i10q-073124.htm Edgar Link pending
gmth-20240731.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
gmth-20240731_def.xml Edgar Link unprocessable
gmth-20240731_cal.xml Edgar Link unprocessable
gmth-20240731_lab.xml Edgar Link unprocessable
gmth-20240731_pre.xml Edgar Link unprocessable
gmtech_i10q-073124_htm.xml Edgar Link completed
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending